Key facts
- Draig Therapeutics’s last known valuation is $44.0M (Apr 2025).
- It has raised $165.9M.
- Notable investors include Canaan Partners, SV Health Investors, SR One Capital Management, Schroders Capital, Access Industries — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Draig Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Draig Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Draig Therapeutics
Developer of a biotechnology platform designed to deliver effective treatments for neuropsychiatric disorders. The company's platform specializes in developing in-class modulators of the primary excitatory and inhibitory neurotransmitters, Glutamate and GABA, to restore synaptic balance and deliver transformative therapeutic benefits, enabling patients with inhibitory neurotransmission issues to get treated effectively.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2021
- Employees
- 31
- Website
- draigtherapeutics.com/
- Ownership
- Privately Held (backing)
Draig Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Draig Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Draig Therapeutics in its N-PORT filings yet. We sweep new filings monthly.